Clinical Trials Directory

Trials / Unknown

UnknownNCT05682612

Prognostic Value of PtcO2 in Patients With COVID-19

Prognostic Value of Transcutaneous Partial Pressure of Oxygen in Patients With Novel Coronavirus Infection

Status
Unknown
Phase
Study type
Observational
Enrollment
40 (estimated)
Sponsor
Southeast University, China · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Five percent of patients with COVID-19 progressed to respiratory failure and required ICU admission, such patients often have abnormal oxygen tolerance. However, there is still a lack of clinical indicators to predict the prognosis and treatment responsiveness of COVID-19.

Detailed description

Five percent of patients with COVID-19 progressed to respiratory failure and required ICU admission. Attention should be paid to patients over 65 years of age who have severe underlying diseases (cancer, respiratory diseases, cardiovascular and cerebrovascular diseases, chronic renal failure, autoimmune deficiency diseases, etc.) and have not completed the whole course of vaccine, and such patients often have abnormal oxygen tolerance, that is, a significant decrease in skin finger pulse oxygen saturation (SpO2) can occur after daily activities. Basal SpO2 at admission is often associated with prognosis, but it is difficult to differentiate prognosis from responsiveness to treatment by changes in SpO2 after oxygen therapy is administered clinically. However, there is still a lack of clinical indicators to predict the prognosis and treatment responsiveness of COVID-19.

Conditions

Interventions

TypeNameDescription
OTHERoutcomehospital survivors and nonsurvivors
OTHERSubtype of COVID-19Different subtype of COVID-19

Timeline

Start date
2023-01-09
Primary completion
2023-12-01
Completion
2023-12-30
First posted
2023-01-12
Last updated
2023-10-12

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05682612. Inclusion in this directory is not an endorsement.